Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna-Lena Volckmar

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Cancer Immunology, Immunotherapy : CII|September 25, 2019
The BRCA2 mutation status shapes the immune phenotype of prostate cancerMaximilian Jenzer, Peter Keß, Cathleen Nientiedt, et al.
Therapeutic Advances in Medical Oncology|August 19, 2021
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancerNikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, et al.
Virchows Archiv : an International Journal of Pathology|September 9, 2017
EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trialJana Fassunke, Michaela Angelika Ihle, Dido Lenze, et al.
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
International Journal of Cancer|November 18, 2018
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panelsVolker Endris, Ivo Buchhalter, Michael Allgäuer, et al.
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsMiriam Blasi, Jonas Kuon, Heike Lüders, et al.
British Journal of Cancer|July 23, 2022
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testingOlaf Neumann, Timothy C Burn, Michael Allgäuer, et al.
Genes, Chromosomes & Cancer|March 9, 2021
KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreasDaniel Schmitz, Daniel Kazdal, Michael Allgäuer, et al.
Plos One|May 3, 2014
Mitochondrial DNA variants in obesityNadja Knoll, Ivonne Jarick, Anna-Lena Volckmar, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Cancer Immunology, Immunotherapy : CII|September 25, 2019
The BRCA2 mutation status shapes the immune phenotype of prostate cancerMaximilian Jenzer, Peter Keß, Cathleen Nientiedt, et al.
Therapeutic Advances in Medical Oncology|August 19, 2021
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancerNikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, et al.
Virchows Archiv : an International Journal of Pathology|September 9, 2017
EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trialJana Fassunke, Michaela Angelika Ihle, Dido Lenze, et al.
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
International Journal of Cancer|November 18, 2018
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panelsVolker Endris, Ivo Buchhalter, Michael Allgäuer, et al.
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsMiriam Blasi, Jonas Kuon, Heike Lüders, et al.
British Journal of Cancer|July 23, 2022
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testingOlaf Neumann, Timothy C Burn, Michael Allgäuer, et al.
Genes, Chromosomes & Cancer|March 9, 2021
KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreasDaniel Schmitz, Daniel Kazdal, Michael Allgäuer, et al.
Plos One|May 3, 2014
Mitochondrial DNA variants in obesityNadja Knoll, Ivonne Jarick, Anna-Lena Volckmar, et al.
Pageof 9